Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.

ABSTRACT:

Objective

Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in terms of radiographically evident quantitative lung involvement. We undertook this study to assess the impact of TCZ on lung function preservation in a post hoc analysis, stratifying treatment arms according to the degree of lung involvement.

Methods

The focuSSced trial was a phase III randomized placebo-controlled trial of TCZ in patients with SSc and progressive skin disease. Participants underwent baseline and serial spirometry along with high-resolution chest computed tomography at baseline and at week 48. Quantitative interstitial lung disease (QILD) and fibrosis scores were assessed by co

SUBMITTER: Roofeh D 

PROVIDER: S-EPMC8238790 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature